Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 10, 2010 - Issue 3
Submit an article Journal homepage
519
Views
18
CrossRef citations to date
0
Altmetric
Drug Evaluations

Teplizumab therapy for type 1 diabetes

Umesh B Masharani University of California San Francisco, Division of Endocrinology and Metabolism, Department of Medicine, 400 Parnassus Avenue, San Francisco, CA 94143, USA +1 415 353 2664; +1 415 353 2337; [email protected]
, MD &
Joseph Becker University of California San Francisco, Division of Endocrinology and Metabolism, Department of Medicine, 400 Parnassus Avenue, San Francisco, CA 94143, USA +1 415 353 2664; +1 415 353 2337; [email protected]
, MD
Pages 459-465 | Published online: 24 Jan 2010

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Shannon A Miller & Erin St. Onge. (2011) Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus. Expert Opinion on Biological Therapy 11:11, pages 1525-1532.
Read now
Dario Tuccinardi, Elvira Fioriti, Silvia Manfrini, Eugenio D'Amico & Paolo Pozzilli. (2011) DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes. Expert Opinion on Biological Therapy 11:9, pages 1233-1240.
Read now

Articles from other publishers (16)

Kevan C. Herold, Stephen E. Gitelman, Peter A. Gottlieb, Laura A. Knecht, Ralph Raymond & Eleanor L. Ramos. (2023) Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function. Diabetes Care 46:10, pages 1848-1856.
Crossref
Saurav Misra & Ajay Kumar Shukla. (2023) Teplizumab: type 1 diabetes mellitus preventable?. European Journal of Clinical Pharmacology 79:5, pages 609-616.
Crossref
Joshua M. Gammon, Sean T. Carey, Vikas Saxena, Haleigh B. Eppler, Shannon J. Tsai, Christina Paluskievicz, Yanbao Xiong, Lushen Li, Marian Ackun-Farmmer, Lisa H. Tostanoski, Emily A. Gosselin, Alexis A. Yanes, Xiangbin Zeng, Robert S. Oakes, Jonathan S. Bromberg & Christopher M. Jewell. (2023) Engineering the lymph node environment promotes antigen-specific efficacy in type 1 diabetes and islet transplantation. Nature Communications 14:1.
Crossref
Arun K. Pande, Deep Dutta & Rajiv Singla. (2023) Prevention of Type 1 Diabetes: Current Perspective. Indian Journal of Endocrinology and Metabolism 27:4, pages 277-285.
Crossref
Simran Thakkar, Aditi Chopra, Lakshmi Nagendra, Sanjay Kalra & Saptarshi Bhattacharya. (2023) Teplizumab in Type 1 Diabetes Mellitus: An Updated Review. touchREVIEWS in Endocrinology 19:2, pages 7.
Crossref
Magdalena M. Samojlik & Cherie L. Stabler. (2021) Designing biomaterials for the modulation of allogeneic and autoimmune responses to cellular implants in Type 1 Diabetes. Acta Biomaterialia 133, pages 87-101.
Crossref
Patricia Gogesch, Simone Dudek, Ger van Zandbergen, Zoe Waibler & Martina Anzaghe. (2021) The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies. International Journal of Molecular Sciences 22:16, pages 8947.
Crossref
Labe A. Black & Tatiana Zorina. (2020) Genetic profile considerations for induction of allogeneic chimerism as a therapeutic approach for type 1 diabetes mellitus. Drug Discovery Today 25:8, pages 1293-1297.
Crossref
I K Manoylov, G V Boneva, I A Doytchinova, N M Mihaylova & A I Tchorbanov. (2019) Protein-engineered molecules carrying GAD65 epitopes and targeting CD35 selectively down-modulate disease-associated human B lymphocytes. Clinical and Experimental Immunology 197:3, pages 329-340.
Crossref
Hamid Hosseini, Li Yi, Peter Kanellakis, Anh Cao, Christopher Tay, Karlheinz Peter, Alex Bobik, Ban‐Hock Toh & Tin Kyaw. (2018) Anti‐TIM‐1 Monoclonal Antibody (RMT1‐10) Attenuates Atherosclerosis By Expanding IgM‐producing B1a Cells. Journal of the American Heart Association 7:13.
Crossref
S. Alice Long, Jerill Thorpe, Kevan C. Herold, Mario Ehlers, Srinath Sanda, Noha Lim, Peter S. Linsley, Gerald T. Nepom & Kristina M. Harris. (2017) Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cellular Immunology 319, pages 3-9.
Crossref
Robert N. Bone & Carmella Evans-Molina. (2017) Combination Immunotherapy for Type 1 Diabetes. Current Diabetes Reports 17:7.
Crossref
TC Hardman & SW Dubrey. (2013) New therapies in the management of type 2 diabetes mellitus. British Journal of Hospital Medicine 74:4, pages 202-207.
Crossref
Jessica W Skelley, Lindsey K Elmore & Jeffrey A Kyle. (2012) Teplizumab for Treatment of Type 1 Diabetes Mellitus. Annals of Pharmacotherapy 46:10, pages 1405-1412.
Crossref
Kai-Jye Lou. (2012) Two-pronged approach to T1D. Science-Business eXchange 5:23.
Crossref
Henk-Jan Schuurman. 2011. Principles of Immunopharmacology. Principles of Immunopharmacology 525 556 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.